OneOncology Takes Center Stage at ASCO 2026
It seems like every year, ASCO unveils a fresh wave of promising research in oncology. This time around, OneOncology and its partner practices are making quite the splash, with 23 abstracts poised to ignite discussions in Chicago from May 29 to June 2. These abstracts aren't just another set of numbers—each one represents a step forward in cancer care and patient accessibility.
An Impressive Spread Across Cancer Types
From lung to hematologic malignancies, these abstracts cover a vast spectrum of cancer types. Whether you're eyeing the complexities of rare cancers or the challenges in breast cancer treatment, OneOncology's breadth of research stretches wide. It’s a power move showcasing the expanding role of community-based research in this evolving field.
The presentations reflect the depth and quality of research being conducted at OneOncology-affiliated practices, said Ian Flinn, MD, PhD.
Flinn's words aren't just fluff. They speak to a truth: community oncology is integral in pushing the boundaries of cancer treatment. These abstracts ain't just papers; they're blueprints for the future.
Key Themes Shaping the Future of Oncology
Diving into the abstracts, three dominant themes emerge. First up, precision oncology. Studies are digging deep, like KRAS G12C-mutant and EGFR-mutated non-small cell lung cancer investigations. Targeted therapies are taking the spotlight alongside innovative combos of immunotherapies.
Then you've got the drive for equity. These aren't just clinical buzzwords—researchers are committed to shaking up the status quo by making trials more inclusive. The focus on social determinants of health is a wake-up call to anyone thinking patients are just data points.
Real-World Innovation: Digital Tools and Outcomes
OneOncology isn't stopping at clinical inclusivity. They're tapping into real-world evidence and digital tools, throwing ePROs and AI into the mix for better clinical decision-making. It’s the 21st century way of saying: let's put patients at the center while embracing tech.
- Advancing precision oncology with biomarker-specific therapies
- Expanding research participation for more inclusive outcomes
- Leveraging real-world data to refine cancer care strategies
Impact Beyond the Headlines
Here's where OneOncology stands out: they're not just about breakthroughs—they’re about reach. Expanding access through trials closer to home in places like Louisiana and Mississippi means patients can stay put instead of taking up half-year residence elsewhere just to live. Victor T. G. Lin, MD, PhD, reminds us that these trials aren't just about survival stats. They’re about real lives, real families.
And the numbers back it up: a 260% boost in trial accruals sure isn't happening in a vacuum. It's the sign of a thriving community-based research network, strengthening its stature, proving that it can contend with the big fish while maintaining a personal touch.
The Road Ahead
Looking to the horizon, OneOncology isn’t just fiddling around on the margins of cancer therapy—they're setting up camp in the center. With over 2,300 providers across 20 states, these guys are a powerhouse, sticking a flag in the ground for community-driven oncology care. Not bad for a concept birthed by community physicians looking to stand independent while shoulder-to-shouldering with hospital giants.
So, here's to seeing where OneOncology’s path will lead. If their current efforts are any indicator, they’ll remain a strong network stitching together quality community care without driving up costs. In this game, that’s a win for everyone, especially those who need it most.
